Sagimet Biosciences Inc. (SGMT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は San Mateo, CA, アメリカ. 現CEOは David A. Happel.
SGMT を有する IPO日 2023-07-17, 14 名の正社員, に上場 NASDAQ Global Market, 時価総額 $177.38M.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
